glp-1 impact on bariatric surgery SSAT Complex GS Fellowship Virtual Grand Rounds Webinar: of GLP1s ESG vs. Bariatric Surgery vs.

Tirzepatide has been shown to support greater average weight loss than placebo, with some participants losing a significant amount of their starting weight

11 On average, patients regain one-third of the weight lost (510% of baseline bodyweight) within the first year of treatment discontinuation, and nearly half of patients return to their initial weight within five years

GLP-1s may reduce both physical and emotional symptoms at the same time

These effects collectively improve blood sugar control in patients with type 2 diabetes

Semaglutide for weight loss Semaglutide is the active ingredient in the brand-name drugs Ozempic, Wegovy, and Rybelsus and in compounded semaglutide

A., Markwardt, M